Dec. 1, 2011 -
PRLog -- GlobalData’s analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow moderately at a CAGR of 3.3% over the next eight years to reach $11.1 billion by 2018. The current competitive landscape consists mainly of bisphosphonates, selective estrogen receptor modulators (SERM), receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL) inhibitor drugs and hormone therapy, which includes parathyroid hormone apart from estrogen and progesterone. The recent launch of Prolia (denosumab), a monoclonal antibody from the therapeutic class RANKL inhibitor, has also opened new avenues for the treatment of osteoporosis with improved safety, efficacy and compliance to medication by the patient. The expected moderate growth can be attributed to an increase in awareness, an ageing population and launch of prominent pipeline molecules such as Odanacatib (MK-0822) and NB S101. The impending patent expiry of Boniva (ibandronate)
in 2012; Actonel (risedronate sodium) and Reclast (zoledronic acid) in 2013; and Evista (raloxifene)
in 2014 will lead to patients having access to treatment at much lower prices reflecting brand erosion of these drugs. The growth in the historic period was also affected by Fosamax (alendronate)
generics, which lost its patent exclusivity in 2008.
GlobalData assessed the current competitive landscape for osteoporosis drugs and found that the competition is strong. The market has several therapeutic options for the treatment of osteoporosis, which includes bisphosphonates such as alendronate, Actonel, Reclast and Boniva as the first line of therapy. It also includes SERMs like Evista; parathyroid hormone like Forteo (teriparatide)
and other drugs containing hormones such as estrogen/progesterone for the treatment of osteoporosis. Prolia, a monoclonal antibody, belonging to the RANKL inhibitor class also presents a convenient choice to the physician for the treatment of osteoporosis patients. The top selling osteoporosis therapeutics drugs have comparable efficacy levels and safety profiles, with only marginal differences, which have intensified the competition in the osteoporosis therapeutics market. Although, these agents do not completely satisfy the patients’ needs, there remains a large percentage of people looking for better treatment options in terms of safety, efficacy and dosage patterns for better compliance. Such patients do not have a choice but to continue with the presently available drugs, which only closely meet their needs. Any drug that could successfully cater to the needs of this patient segment is expected to capture a major revenue share of the osteoporosis therapeutics market.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....GlobalData’s analysis shows that the osteoporosis therapeutics pipeline is strong with 57 molecules in the various phases of clinical development. There are three products which are awaiting regulatory approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) in the Europe. They are Fablyn (bazedoxifene)
, Viviant (lasofoxifene)
and EX101 (alendronate in effervescent form). Fablyn and Viviant have been filed for approval with the US FDA. One of the first-in-class molecules, Odanacatib (MK-0822), which is a cathepsin K enzyme inhibitor is in the late stages of clinical development and is expected to enter the market during the late forecast period.
GlobalData, the industry analysis specialist, has released its new report, “Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global osteoporosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoporosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Oste...Visit our report store:
http://www.globaldata.com/reportstoreFor more details contact:
pressreleases@
globaldata.com
North America: +1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782
# # #
GlobalData is a global market intelligence services company providing information research and analysis products and services.
Account Phone Number